🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Joby Aviation cut at JPMorgan as commercial opportunity still a ways off

Published 07/19/2023, 06:50 PM
© Reuters.
BLDE
-
JOBY
-
ACHR
-

Shares of eVTOL maker Joby Aviation (NYSE:JOBY) are up 200% year-to-date amid investor enthusiasm around progress toward commercial operations. However, analysts think the move is too far too fast, given that the commercial opportunity is at least 5 years off, and are using the opportunity to downgrade the stock to a sell-equivalent.

JP Morgan analysts downgraded JOBY to Underweight from Neutral on Wednesday, while setting a $6 price target (up from $5). The new price target suggests 40% downside from yesterday’s closing price.

“In our discussions with institutional investors over the past few months, which have picked up meaningfully in recent weeks, we sense a lot of skepticism around the timing and size of the commercial opportunities for eVTOL, at least within this decade,” analysts commented.

While Joby and peer Archer Aviation (NYSE:ACHR) are still leading the race for FAA certification in the U.S., they see limited short-term upside for ACHR and downgrade JOBY to Underweight. They do, however, acknowledge Joby's strong management, certification progress, and recent advancements in technology. That said, their expectation aligns with the FAA's Advanced Air Mobility Implementation Plan, which sets 2028 as the target year for significant operational growth in eVTOL commercialization.

The analysts continue to see “relative value” in ACHR, which they see as “neck-and-neck” with JOBY, and continue to rate that stock an Overweight.

In addition, analysts think Overweight-rated Blade (NASDAQ:BLDE) offers a potentially safer near-term opportunity to participate in the advanced air mobility trend, focusing on helicopters. It benefits from established passenger routes and infrastructure in key markets that can eventually transition to electric aviation. Additionally, Blade has an underappreciated non-cyclical business involving organ transport.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.